LAVA Therapeutics NV (LVTX) Insider Trading & SEC Filings

Updated Jul 16, 2026 · Last SEC filing 2025-11-17

LAVA Therapeutics NV (LVTX) — no SEC Form 4 insider filings recorded in the last 90 days. InsiderAlpha tracks every LVTX SEC filing — Form 4, Form 144, and 8-K — in real time, including Rule 10b5-1 plan detection.

About LAVA Therapeutics NV (LVTX)

SIC classification	Pharmaceutical Preparations (SIC 2834)
SEC CIK	0001840748

Recent LVTX Insider Transactions (Form 4)

Date	Insider	Role	Transaction	Shares	Price	Value	Filing
2025-10-17	Cooperatieve Gilde Healthcare IV U.A.	Insider	S — Open-market sale	1.18M	$1.47	$1.74M	SEC
2025-10-16	Cooperatieve Gilde Healthcare IV U.A.	Insider	S — Open-market sale	690.2K	$1.49	$1.03M	SEC
2025-10-14	Cooperatieve Gilde Healthcare IV U.A.	Insider	S — Open-market sale	227.3K	$1.51	$343K	SEC
2025-10-13	Cooperatieve Gilde Healthcare IV U.A.	Insider	S — Open-market sale	47.7K	$1.54	$73K	SEC
2025-10-10	Cooperatieve Gilde Healthcare IV U.A.	Insider	S — Open-market sale	49.9K	$1.55	$77K	SEC
2025-10-09	Cooperatieve Gilde Healthcare IV U.A.	Insider	S — Open-market sale	48.2K	$1.56	$75K	SEC
2025-10-08	Cooperatieve Gilde Healthcare IV U.A.	Insider	S — Open-market sale	29.0K	$1.57	$45K	SEC
2025-09-19	Versant Venture Capital VI, L.P.	Insider	S — Open-market sale	2.37M	$1.40	$3.32M	SEC
2025-09-19	Versant Venture Capital VI, L.P.	Insider	S — Open-market sale	532.9K	$1.40	$747K	SEC
2025-09-18	Versant Venture Capital VI, L.P.	Insider	S — Open-market sale	366.1K	$1.44	$528K	SEC
2025-09-18	Versant Venture Capital VI, L.P.	Insider	S — Open-market sale	228.8K	$1.44	$330K	SEC
2025-09-17	Versant Venture Capital VI, L.P.	Insider	S — Open-market sale	226.7K	$1.49	$338K	SEC
2025-09-17	Versant Venture Capital VI, L.P.	Insider	S — Open-market sale	362.8K	$1.49	$540K	SEC
2025-09-16	Versant Venture Capital VI, L.P.	Insider	S — Open-market sale	307.7K	$1.53	$472K	SEC
2025-09-16	Versant Venture Capital VI, L.P.	Insider	S — Open-market sale	192.3K	$1.53	$295K	SEC

All transactions sourced from SEC EDGAR Form 4 filings for LAVA Therapeutics NV (LVTX). Updated in real time as new filings are submitted to the SEC.

Recent Insider Filings

2025-11-17 — Powell Fred M (Chief Financial Officer)
2025-11-17 — HURLY STEPHEN A (Chief Executive Officer)
2025-11-17 — WILSON KAREN J (Insider)
2025-11-17 — Kiener Peter A (Insider)
2025-11-17 — Noble James (Insider)

Form 4 Transaction Code Reference

SEC Form 4 transactions are reported with a one-letter code indicating the type of transaction. Common codes you'll see in LVTX insider filings:

P	Open-market purchase by the insider
S	Open-market sale by the insider
A	Grant, award, or other acquisition from the issuer
M	Exercise or conversion of derivative security (e.g. options)
F	Payment of exercise price or tax liability via share withholding
G	Bona-fide gift of securities
D	Disposition to the issuer (e.g. share buyback participation)
J	Other acquisition or disposition
X	Exercise of in-the-money or at-the-money derivative security
C	Conversion of derivative security
V	Transaction voluntarily reported earlier than required

LVTX Insider Trading — FAQ

What is the latest insider trade for LVTX?: LAVA Therapeutics NV (LVTX) had 0 insider filings in the last 90 days, with the most recent on 2025-11-17. InsiderAlpha tracks every Form 4, 10-K, 10-Q, and 8-K filing in real time.
How many insiders are buying LVTX stock?: 0 insider purchases of LVTX were filed in the last 90 days.
How many insiders are selling LVTX stock?: 0 insider sales of LVTX were filed in the last 90 days.
Where can I see LVTX SEC filings (Form 4, 10-K, 10-Q, 8-K)?: InsiderAlpha aggregates every LVTX SEC filing — Form 4 insider transactions, 10-K and 10-Q quarterly reports, and 8-K material event disclosures — in one timeline.

Related Companies — Recent Insider Activity

Learn More

Open the live LVTX dashboard on InsiderAlpha for real-time alerts, charting, and full historical filing search.